About Innocoll

Innocoll is a biotherapeutics pharmaceutical company committed to improving the status quo and finding answers to unmet needs

About Us

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

XARACOLL

Latest News

Innocoll Announces Positive Topline Results for Xaracoll® (Bupivacaine Hydrochloride) Implant in a Phase 3 Study to Support Expanded Use

2 Mar
XARACOLL 300mg Dose Cohort Experienced Less Pain and XARACOLL was Generally Well Tolerated with an Adverse Event Profile Comparable to...
Read More

Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio

25 Feb
Positions Innocoll as a comprehensive hernia solutions company including products for surgery and open inguinal hernia repair pain relief Innocoll...
Read More

Innocoll Announces Successful Completion of Debt Refinancing

22 Feb
$125 million refinancing substantially improves Innocoll’s liquidity, enabling further investment in pharmaceutical technology portfolio and growth plan ATHLONE, Ireland –...
Read More

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited